Katie Couric skinpeel

July 18, 2007 – 5:28 pm

Katie Couric  uses the Silkpeel system.  It's is microdermabrasion system involving a rejuvenating, 20-minute, simultaneous exfoliation and serum infusion, which is delivered using a diamond wand. 
 

It eliminates the need for abrasive particles while allowing for a customized serum infusion to effectively treat not only fine wrinkles caused by dry skin, but also hyperpigmentation,and acne. Silkpeel rapidly removes uneven patches of skin, signs of sun damage, fine lines, and break outs. Additional benefits include reduction of puffiness and firmer muscle

By | Posted in Uncategorized | Comments (0)

Accutane raises Cholesterol And Triglycerid

September 13, 2006 – 9:51 am

A recent entry in the august issue of the Archives of Dermatology highlights a study carried out by research staff at the University of California, San Francisco. Their research showed that the risk of raised cholesterol and/or triglyceride levels in the blood was higher than previouslty espected. 

Dr. Lee T. Zane, said "Having abnormal tests results does not necessarily signal a bad medical outcome. It's just lab tests, not heart attacks. Isotretinoin is undeniably the most effective medication we have for treating severe acne. It can truly be life-changing. We can't lose sight of the fact that isotretinoin is the most important revolution in medical dermatology in the last 30 years."

Accutane should not be taken by pregnant women as it has been linked to birth defects.

The team of researchers say that do not know if children who take Accutane will increase their chances of developing cardiovascular problems when they become adults.

By acnemaven | Posted in News | Comments (3)

AlphaRx Inc receives notice of allowance for patent application “Stabilization of Benzoyl Peroxide in Solution”

September 12, 2006 – 10:32 am

MARKHAM, Ontario, Jan. 25, 2006 (PRIMEZONE) — AlphaRx Inc. (OTCBB:ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application entitled “Vehicle For Topical Delivery of Anti-Inflammatory Compounds.” The platform is an integral part of the Company’s lead product Indaflex(tm), which is undergoing a Phase II clinical trial.

Michael Lee, President of AlphaRx Inc., stated, “We are extremely pleased about the allowance of this patent. This award helps protect our innovative drug delivery technology and further endorses our competitive position. We have 6 further patent applications pending and are hopeful that this is the first of many patents that will be receiving allowance.”

About Indaflex(tm)

Indaflex(tm) is AlphaRx’s topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation under clinical development for the symptomatic treatment of osteoarthritis. Arthritis is the most common chronic disease in North America and afflicts an estimated 10% of the world’s population. Indaflex’s active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. With AlphaRx’s enhanced proprietary delivery system, the company believes its’ clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex(tm) delivery, the company hopes, may circumvent the significant GI side-effects commonly found with orally ingested NSAID’s.

About AlphaRx Inc.

AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company’s product candidates address various pharmaceutical markets, including arthritis, tuberculosis, ocular infection and inflammation, cataracts, hospital acquired pneumonia and sepsis.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

This press release is available on the company’s official on-line investor relations site for investor commentary, feedback and questions.

 

 

By acnemaven | Posted in News | Comments (1)